Lindsay A. Rosenwald, M.D.

Executive Chairman and Interim Chief Executive Officer

Dr. Lindsay Rosenwald has served as the Executive Chairman and Interim Chief Executive Officer of Oncogenuity since its inception in May 2020. Over the last 25 years, Dr. Rosenwald has been an active biotechnology entrepreneur, founding and recapitalizing numerous public and private life sciences companies. He has been a member of the Board of Directors of Fortress Biotech since October 2009, as well as Chairman, President, and Chief Executive Officer since December 2013. He also serves as a director of Mustang Bio, Inc., Chairman of the Board of Directors of Avenue Therapeutics, Inc., and a director of Checkpoint Therapeutics, Inc. From November 2014 to August 2015, Dr. Rosenwald served as Interim President and Chief Executive Officer of Checkpoint Therapeutics, Inc., and from 1991 to 2008, Dr. Rosenwald served as the Chairman of Paramount BioCapital, Inc. Dr. Rosenwald received his Bachelor of Science in Finance from Pennsylvania State University and his Doctor of Medicine from Temple University School of Medicine.

Arthur (A.J.) Ross

Chief Business Officer

Arthur Ross has served as the Chief Business Officer of Oncogenuity since inception in May 2020. He also remains a Vice President of Business Development at Fortress Biotech, which he joined in 2015. Mr. Ross joined Fortress Biotech from Cowen & Company where he worked on the equity capital markets desk, focused on life sciences. During his tenure, Cowen & Company was among the most active broker-dealers in the space, raising over $4B for life sciences companies in twelve months. Before working at Cowen & Company, Mr. Ross was an investment banking analyst at ROTH Capital. Mr. Ross holds a Bachelor of Science in mathematical economics from Colgate University.